Compugen (CGEN) Stock Price, News & Analysis

Company Overview

Compugen Ltd. is an Israeli clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for cancer and other serious diseases. The company uses computational biology, data analysis and related technologies to identify novel drug targets and develop antibody-based medicines, with an emphasis on immuno-oncology.

Compugen’s pipeline includes investigational immune checkpoint therapies designed to reactivate anti-tumor immune responses. Its leading programs have included COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT. These candidates are being evaluated in clinical studies, including combination approaches intended to address solid tumors. Compugen does not currently operate as a broad commercial pharmaceutical company; its activities are primarily centered on research, development and strategic collaborations.

Founded in 1993, Compugen is headquartered in Holon, Israel, and its securities trade on the Nasdaq Capital Market under the symbol CGEN. The company’s drug-development programs and collaborations have an international focus, with clinical and business activities extending beyond Israel. Anat Cohen-Dayag has served as Compugen’s president and chief executive officer and has led the company’s transition toward a therapeutics-focused biotechnology business.

Key Stats

• Today's Range: $2.31 to $2.47
• 50-Day Range: $2.24 to $2.87
• 52-Week Range: $1.37 to $3.23
• Volume: 288,219 shs
• Average Volume: 209,010 shs
• Market Capitalization: $221.25 million
• P/E Ratio: 6.16
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Compugen Stock Analysis - MarketRank™

Compugen scored higher than 84% of companies evaluated by MarketBeat, and ranked 62nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Compugen has a consensus price target of $5.00, representing about 113.7% upside from its current price of $2.34.

Amount of Analyst Coverage

Compugen has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Compugen are expected to grow in the coming year, from ($0.27) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compugen is 6.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compugen is 6.16, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.58.

Price to Book Value per Share Ratio

Compugen has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.75% of the float of Compugen has been sold short.

Short Interest Ratio / Days to Cover

Compugen has a short interest ratio ("days to cover") of 6.11.

Change versus previous month

Short interest in Compugen has recently decreased by 22.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compugen does not currently pay a dividend.

Dividend Growth

Compugen does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.34

News Sentiment

Compugen has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Compugen this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for CGEN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

1 people have added Compugen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Compugen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,688.00 in company stock.

Percentage Held by Insiders

9.50% of the stock of Compugen is held by insiders.

Percentage Held by Institutions

12.22% of the stock of Compugen is held by institutions.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/23/2026
• Investor update: 10/05/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CGEN
• CIK: 1119774
• Web: www.cgen.com
• Phone: (723) 765-8585
• Fax: 972-3765-8555
• Employees: 75
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Compugen: $5.00
• High Price Target: $6.00
• Low Price Target: $4.00
• Potential Upside/Downside: +113.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.38
• Trailing P/E Ratio: 6.16
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $35.34 million
• Net Margins: 47.56%
• Pretax Margin: 47.62%
• Return on Equity: 42.57%
• Return on Assets: 26.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.72
• Quick Ratio: 5.72

Sales & Book Value

• Annual Sales: $72.76 million
• Price / Sales: 3.04
• Cash Flow: $0.35 per share
• Price / Cash Flow: 6.66
• Book Value: $1.09 per share
• Price / Book: 2.15

Miscellaneous

• Outstanding Shares: 94,550,000
• Free Float: 85,570,000
• Market Cap: $221.25 million
• Optionable: Optionable
• Beta: 2.78